



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|----|---|
| <p>(51) International Patent Classification ⁶ : C12N 15/12, C07K 14/805, A61K 38/42, 48/00, C12N 15/86, 5/10 // 15/85, 15/87</p> | A1 | <p>(11) International Publication Number: WO 96/09385</p> <p>(43) International Publication Date: 28 March 1996 (28.03.96)</p> |
| <p>(21) International Application Number: PCT/US95/11873</p> <p>(22) International Filing Date: 19 September 1995 (19.09.95)</p> <p>(30) Priority Data: 08/308,795 19 September 1994 (19.09.94) US</p> <p>(71) Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US).</p> <p>(72) Inventors: LEBOULCH, Philippe; Apartment 417, 10 Rogers Street, Cambridge, MA 02142 (US). LONDON, Irving, M.; 41 Fresh Pond Lane, Cambridge, MA 02138 (US).</p> <p>(74) Agents: ARNOLD, Beth, E. et al.; Lahive & Cockfield, 60 State Street, Boston, MA 02109 (US).</p> | | <p>(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report.</i></p> |
| <p>(54) Title: ANTI-SICKLING BETA-GLOBIN PROTEIN, COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASE</p> <p>(57) Abstract</p> <p>Gene therapy methods and compositions for high level expression of anti-sickling beta-globin proteins in erythroid cells for treating Sickle Cell Disease are described.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgystan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LU | Luxembourg | SN | Senegal |
| CN | China | LV | Latvia | TD | Chad |
| CS | Czechoslovakia | LU | Luxembourg | TG | Togo |
| CZ | Czech Republic | LV | Latvia | TJ | Tajikistan |
| DE | Germany | MC | Monaco | TT | Trinidad and Tobago |
| DK | Denmark | MD | Republic of Moldova | UA | Ukraine |
| ES | Spain | MG | Madagascar | US | United States of America |
| FI | Finland | ML | Mali | UZ | Uzbekistan |
| FR | France | MN | Mongolia | VN | Viet Nam |
| GA | Gabon | | | | |

Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease

Background of the Invention

5

The sickling of erythrocytes in Sickle Cell Disease (SCD) is the result of a single amino-acid mutation, β 6 [Glu to Val], which leads to the polymerization of hemoglobin S ($\alpha_2\beta^S_2$) in the tense (T), deoxygenated state. Long, multi-stranded fibers form within red blood cells (RBCs) of patients with SCD. The main fibers are made of 14 twisted strands associated by pairs (the Wisner-Lowe double-strand). The β 6 Val mutation is required to initiate stable lateral contacts with another tetramer in the double-stranded unit. Only one β 6 Val mutation per $\alpha_2\beta^S_2$ tetramer is involved in inter-tetramer contact, although many other amino-acid residues participate in lateral and axial contacts within the double-strand as well as between double-strands (Bunn, H.F. and Forget, B.G. (1986) *Hemoglobin: Molecular, Genetic and Clinical Aspects*, (W.B. Saunders Company, Philadelphia); Bunn, H.F. (1994) in *The Molecular Basis of Blood Diseases*, Second Edition, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Majerus, P.W. and Varmus, H. (W.B. Saunders Company, Philadelphia), pp. 207-256; Dickerson, R.E. and Geis, I. (1983) *Hemoglobin: Structure, Function, Evolution, and Pathology* (The Benjamin/Cummings Publishing Company, Inc., Menlo Park, California); Schechter, A.N., Noguchi, C.T. and Rodgers, G.P. (1987) in *The Molecular Basis of Blood Diseases*, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Leder, P. and Majerus, P.W. (W.B. Saunders Company, Philadelphia), pp. 179-218).

Mixing β^S with the other normal human β -like globin chains (β^x), i.e. β^- , δ^- or γ^- , results in an equilibrium between symmetrical ($\alpha_2\beta^S_2$ and $\alpha_2\beta^x_2$) and hybrid ($\alpha_2\beta^S\beta^x$) tetramers, because interactions at α/β subunit interfaces within the same hemoglobin tetramer (packing and lateral contacts) are similar among β -like globin chains. Symmetrical tetramers that do not have the β 6 Val mutation ($\alpha_2\beta^x_2$) are incorporated into the fibers very poorly. The $\alpha_2\beta^S\beta^x$ hybrid tetramers are capable of copolymerizing with hemoglobin S, because only one β 6 Val residue per tetramer is required for inter-tetramer contact, and the other lateral and axial contacts are formed efficiently with the trans β subunit. In contrast, $\alpha_2\beta^S\gamma$ and $\alpha_2\beta^S\delta$ hybrid tetramers are poorly if at all incorporated, because trans δ^- and γ^- globin chains are unable to form important contacts within the S fiber even when the β 6 Val residue of the β^S subunit is aligned appropriately. This phenomenon is believed to explain why γ^- and δ^- globins are much stronger inhibitors of sickling than β^- globin, *in vitro*. In addition, interaction of these hybrid tetramers with hemoglobin S without successful copolymerization is expected to delay the polymerization process *in vivo*, so that RBCs return to the lung to get reoxygenated before significant sickling has occurred (Benesch, R.E., Edalji, R., Benesch, R. and Kwong, S. (1980) *Proc. Natl. Acad. Sci. USA*, 77, 5130-5134; Cheetham, R.C., Huehns,

35

E.R. and Rosemeyer, M.A. (1979) *J. Mol. Biol.*, 129, 45-61; Sunshine, H.R., Hofrichter, J. and Eaton, W.A. (1979) *J. Mol. Biol.*, 133, 435-467; Bunn, H.F. and Forget, B.G. (1986) *Hemoglobin: Molecular, Genetic and Clinical Aspects*, (W.B. Saunders Company, Philadelphia); Bunn, H.F. (1994) in *The Molecular Basis of Blood Diseases*, Second Edition, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Majerus, P.W. and Varmus, H. (W.B. Saunders Company, Philadelphia), pp. 207-256; Dickerson, R.E. and Geis, I. (1983) *Hemoglobin: Structure, Function, Evolution, and Pathology* (The Benjamin/Cummings Publishing Company, Inc., Menlo Park, California); Schechter, A.N., Noguchi, C.T. and Rodgers, G.P. (1987) in *The Molecular Basis of Blood Diseases*, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Leder, P. and Majerus, P.W. (W.B. Saunders Company, Philadelphia), pp. 179-218).

The actual inhibitory effect of δ chains has not yet been assessed *in vivo*, because the δ -globin gene is always expressed at very low levels in human RBCs. In contrast, there is a strong correlation between high expression levels of γ chains and a lower propensity for sickling *in vivo*, as observed for instance in certain forms of SCD associated with hereditary persistence of fetal hemoglobin (HPFH) (Bunn, H.F. and Forget, B.G. (1986) *Hemoglobin: Molecular, Genetic and Clinical Aspects*, (W.B. Saunders Company, Philadelphia); Bunn, H.F. (1994) in *The Molecular Basis of Blood Diseases*, Second Edition, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Majerus, P.W. and Varmus, H. (W.B. Saunders Company, Philadelphia), pp. 207-256; Dickerson, R.E. and Geis, I. (1983) *Hemoglobin: Structure, Function, Evolution, and Pathology* (The Benjamin/Cummings Publishing Company, Inc., Menlo Park, California); Schechter, A.N., Noguchi, C.T. and Rodgers, G.P. (1987) in *The Molecular Basis of Blood Diseases*, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Leder, P. and Majerus, P.W. (W.B. Saunders Company, Philadelphia), pp. 179-218).

In addition, drugs known to derepress partially γ -globin gene expression, such as hydroxyurea and butyrate derivatives, are clearly beneficial to SCD patients. However, these approaches do not represent a definitive cure and have raised legitimate concerns regarding their potential long-term consequences, which include teratogenic and oncogenic effects for hydroxyurea and neurotoxicity and multiorgan damage for butyrate. In addition, drug induced γ -globin expression might be largely restricted to F cells, so that non-F cells may still sickle in SCD (Stamatoyannopoulos, G. and Nienhuis, A., W., (1994) in *The Molecular Basis of Blood Diseases*, Second Edition, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Majerus, P.W. and Varmus, H. (W.B. Saunders Company, Philadelphia), pp. 107-155).

New therapies for treating a subject afflicted with sickle cell disease are needed.

Summary of the Invention

5 In general, the invention relates to gene therapy methods and compositions for treating a subject afflicted with Sickle Cell disease. High level expression of anti-sickling globin proteins as described herein can effectively interfere with the polymerization of hemoglobin S and thereby reduce or eliminate the symptoms associated with Sickle Cell disease.

10 In one aspect, the invention features new anti-sickling globin proteins comprising conformationally correct β globin in which at least one amino acid residue has been substituted with a corresponding residue (an anti-sickling residue) from a δ - or γ -globin. In a preferred embodiment, the β , δ and γ globins are human. In another preferred embodiment, the anti-sickling residue is selected from the group consisting of: 9 Thr, 12 Asn,
15 22 Ala, 50 Ser, 80 Asp, 86 Ser, 87 Gln, 116 Arg, 117 Asn, 125 Gln, 126 Met. In a particularly preferred embodiment, the anti-sickling β -globin protein comprises the 146 amino acids of β -globin with the following substitutions: 9 Thr, 12 Asn, 22 Ala, 50 Ser, 86 Ser, 87 Gln, 116 Arg and 117 Asn.

20 In another aspect, the invention relates to genetic material encoding anti-sickling β -globin proteins. In one embodiment, the genetic material is deoxyribonucleic acid (DNA). In another embodiment, the genetic material is ribonucleic acid (RNA)

25 In a further aspect, the invention relates to gene constructs comprising genetic material encoding anti-sickling β -globin proteins and an appropriate transcriptional control element. In a first embodiment, the genetic material encoding an anti-sickling β -globin protein is DNA and the transcriptional control element is a promoter recognized by a DNA polymerase. In a preferred embodiment, the DNA polymerase is erythroid specific. In a particularly preferred embodiment, the promoter is the β - globin promoter or HPFH
30 promoter. In a second embodiment, the genetic material encoding an anti-sickling β -globin protein is RNA and the transcriptional control element is a promoter recognized by an RNA polymerase. A gene construct encoding an anti-sickling β -globin protein can additionally comprise an enhancer sequence. In a preferred embodiment, the enhancer sequence is the DNase I hypersensitive site 2 of the human β Locus Control Region. A gene construct
35 encoding an anti-sickling β -globin protein can also encode a selectable marker, which is useful in ex vivo gene therapy procedures for selecting erythroid cells containing the anti-sickling encoding construct.

In yet another aspect, the invention relates to vectors comprising elements for introducing and stably maintaining a gene construct encoding an anti-sickling β -globin protein into an erythroid cell and a gene construct encoding an anti-sickling β -globin protein. Preferred gene therapy vectors are selected from the group consisting of: retrovirus, adenovirus, adeno-associated virus, naked plasmid, lipid delivery of plasmid (including via liposomes), receptor mediated delivery of plasmid, alone, or in conjunction with transferring DNA-polylysine complexes linked to adenovirus capsids. A particularly preferred vector comprises retroviral elements.

In still another aspect, the invention relates to gene therapy methods for treating a subject with sickle cell disease. In one embodiment, erythroid cells from a subject or from a donor are obtained and are contacted with a suitable vector encoding an anti-sickling β -globin protein in vitro. Erythroid cells expressing the anti-sickling β -globin proteins are then selected (e.g. based on expression of an anti-sickling β -globin protein or a selectable marker that has been included in the gene construct) and infused into the subject (e.g. via graft or transplantation). In another embodiment, a vector encoding an anti-sickling β -globin protein is administered directly to a subject in vivo.

Other features and advantages will be readily apparent from the following detailed description and claims.

Brief Description of the Drawings

Figure 1 is a graphic representation of the amino-acid sequence alignment of human β -, β^S - and δ -globins. The two amino-acids residues δ 125Gln and δ 126Met that were not incorporated in the [β/δ -SC11/HS2] retroviral vector are indicated within brackets [QM]. Anti-sickling residues δ 87Gln and δ 22Ala are indicated by an asterisk and a vertical, dashed line. The α/β packing and sliding contacts within the globin tetramer are indicated by "+"; contacts present only in the relaxed (R) "oxy" or tense (T) "deoxy" states are indicated by R or T, respectively; the β_1 and β_2 , lateral and axial contacts within the Wisner-Lowe double-strands of the Hb S polymer are indicated by a "+".

Figure 2 shows a schematic representation of the structure of the [β/δ -globin/HS2] retroviral vector, p#147.

35

Detailed Description of the Invention

The instant invention is based on the finding that retroviral transfer of genetic material encoding anti-sickling β -globin protein into erythroid cells results in high and

erythroid specific expression of an anti-sickling β -globin protein. Based on this finding, the invention features anti-sickling β -globin proteins; methods for making the proteins; constructs and vectors useful in making the proteins; and methods for delivering the constructs to erythroid cells for treating sickle cell disease

5

Anti-sickling β -globin proteins

The γ - and δ -globin chains have been found to be more potent inhibitors of sickling than β chains in vitro (Benesch, R.E., Edalji, R., Benesch, R. and Kwong, S. (1980) Proc. Natl. Acad. Sci. USA, 77, 5130-5134; Cheetham, R.C., Huehns, E.R. and Rosemeyer, M.A. (1979) J. Mol. Biol., 129, 45-61; Sunshine, H.R., Hofrichter, J. and Eaton, W.A. (1979) J. Mol. Biol., 133, 435-467). However, both γ -globin and δ -globin genes are expressed at very low levels in normal adult RBCs.

15 However, as shown herein, high expression levels of anti-sickling β -globin chain proteins with anti-sickling properties can be obtained from expressions of constructs that maintain the general structure of the β -globin gene and its cis-acting elements, while substituting nucleotides encoding "anti-sickling" amino-acid residues from either γ or δ chains for corresponding codons in the β -globin gene.

20

Nagel and colleagues have attempted to assign the anti-sickling effect of δ and γ chains to specific amino-acid residues (Nagel, R.L., Bookchin, R.M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W.A., Honig, G.R., Schiliro, G., Crookston, J.H. and Matsutomo, K. (1979) Proc. Natl. Acad. Sci., USA, 76, 670-672). Because of the few differences between β and δ chains (10 of their 146 residues) and the existence of natural β/δ hybrid chains, the Lepore globins, Nagel and colleagues have succeeded in assigning most of the in vitro anti-sickling properties of δ chains to residues δ 22Ala and δ 87Gln, with possible additional contribution of δ 12Asn (Nagel, R.L., Bookchin, R.M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W.A., Honig, G.R., Schiliro, G., Crookston, J.H. and Matsutomo, K. (1979) Proc. Natl. Acad. Sci., USA, 76, 670-672). Interestingly, β 87 and β 22 are believed to occupy critical positions for contacts between tetramers in the HbS fiber, both within the Wisher-Lowe double-strand (for β 87 and β 22) (Bunn, H.F. and Forget, B.G. (1986) Hemoglobin: Molecular, Genetic and Clinical Aspects, (W.B. Saunders Company, Philadelphia); Bunn, H.F. (1994) in The Molecular Basis of Blood Diseases, Second Edition, eds. Stamatoyannopoulos, G., Nienhuis, A., W., Majerus, P.W. and Varmus, H. (W.B. Saunders Company, Philadelphia), pp. 207-256; Dickerson, R.E. and Geis, I. (1983) Hemoglobin: Structure, Function, Evolution, and Pathology (The Benjamin/Cummings Publishing Company, Inc., Menlo Park, California); Schechter, A.N., Noguchi, C.T. and Rodgers, G.P. (1987) in The Molecular Basis of Blood Diseases, eds. Stamatoyannopoulos,

35

G., Nienhuis, A.W., Leder, P. and Majerus, P.W. (W.B. Saunders Company, Philadelphia), pp. 179-218) and for inter-strand packing ($\beta\beta 87$) (Cretegny, I. and Edelstein, S.J. (1993) J. Mol. Biol., 230, 733-738) (Figure 1).

5 γ and β chains have differing amino acids in 39 out of the total 146 residues. Interestingly, the same amino-acid change exists at position 87 in the γ - and δ -globins as compared to β -globin (δ 87Gln and γ 87Gln versus β 87Thr), and this substitution also appears critical for the anti-sickling activity of γ -globin (Nagel, R.L., Bookchin, R.M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W.A., Honig, G.R., Schiliro, G.,
10 Crookston, J.H. and Matsutomo, K. (1979) Proc. Natl. Acad. Sci., USA, 76, 670-672). However, other residues cooperate with γ 87Gln to provide the maximum effect, including γ 80Asp and other unassigned residues (Nagel, R.L., Bookchin, R.M., Johnson, J., Labie, D., Wajcman, H., Isaac-Sodeye, W.A., Honig, G.R., Schiliro, G., Crookston, J.H. and
15 Matsutomo, K. (1979) Proc. Natl. Acad. Sci., USA, 76, 670-672).

Figure 1 is a graphic representation of the amino-acid sequence alignment of human β -, β^S - and δ -globins. Based on the known amino acid sequence of β -globin and δ -globin, anti-sickling globin proteins can be designed.

20 Example 1 describes the design of a δ -globin/ β -globin hybrid gene, β/δ -SC11, which encodes an anti-sickling β -globin protein comprising the 146 amino acids of β -globin with the following substitutions: 9 Thr, 12 Asn, 22 Ala, 50 Ser, 86 Ser, 87 Gln, 116 Arg and 117 Asn. High expression levels of this construct were achieved in adult erythroid cells. Evaluation of expression level as described herein can provide a preliminary assay for
25 identifying other constructs encoding anti-sickling β -globin proteins. Further evaluation of candidate constructs showing high expression can be carried out for example in transgenic animal models of Sickle Cell disease. Expression of constructs encoding effective anti-sickling β -globin proteins will minimize or ameliorate the sickle cell condition.

30 *Gene Constructs*

Genetic material (i.e. DNA or RNA) encoding anti-sickling β -globin proteins can be synthesized using known techniques. Alternatively, the material can be isolated from natural sources and be further manipulated (e.g. via site-specific mutagenesis). Gene
35 constructs comprising the genetic material and an appropriate transcriptional control element can then be generated. Where the genetic material is DNA, an appropriate transcriptional control element is a promoter recognized by a DNA polymerase. For safety reasons, the DNA polymerase is preferably erythroid specific (i.e. is only expressed in erythroid cells). Known erythroid specific promoters include the β - globin promoter or HPFH promoter. If

the genetic material encoding an anti-sickling β -globin protein is RNA an appropriate promoter must be recognized by an RNA polymerase.

5 In addition to a promoter, a gene construct encoding an anti-sickling β -globin protein can additionally comprise an enhancer sequence. In a preferred embodiment, the enhancer sequence is the DNase I hypersensitive site 2 of the human β Locus Control Region. Another enhancer that can be included in a construct in addition to or in place of the DNase I hypersensitive site 2 of the human β Locus Control Region, is the second intron of the β -globin gene (BIVS2).

10 A gene construct encoding an anti-sickling β -globin protein can also encode a selectable marker (e.g. neomycin, methotrexate) which is useful in ex vivo gene therapy procedures for selecting erythroid cells containing the anti-sickling encoding construct.

15 *Vectors*

A preparation of an anti-sickling β -globin gene can be incorporated in a suitable vector for delivering the gene to appropriate cells ex vivo or in vivo for treating a subject suspected or known to have sickle cell disease (SCD). Appropriate gene therapy vectors preferably are capable of infecting erythroid cells (e.g. stem cells and more differentiated cells of the red blood cell lineage (such as BFUs (burst forming unit), CFUs (colony forming unit), nucleated red blood cells and mature red blood cells). For use in clinical treatment, appropriate vectors must also be appropriately maintained in erythroid cells and be safe. Appropriate vectors for use in the instant invention include: retrovirus; 25 adenovirus (Berkner, K.L. (1988) *BioTechniques* 6:616); adeno-associated virus (Muzyczka, N. (1992) in *Current Topics in Microbiology and Immunology* 158:97); naked plasmid (Wolff, J. et al. (1989) *Science* 247:1465); lipid delivery of plasmid (including via liposomes) (Felgner, P. and Ringold, G.M. (1989) *Nature* 337:387); receptor mediated delivery of plasmid, alone (Wu, G. and Wu, C.H. (1988) *J. Biol. Chem.* 263:14621) or in conjunction 30 with transferring DNA-polylysine complexes linked to adenovirus capsids (Curiel, D.T. et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8850); or any other vector that can infect and be maintained in erythroid cells and does not adversely effect the host.

35 Preferred gene therapy vectors for delivery of genetic material encoding anti-sickling β -globin proteins are defective retroviruses, which are the best characterized system to date and so far the only one approved for use in human gene therapy (Miller, A.D. (1990) *Blood* 76:271). Several requirements need to be met for successful gene therapy using retrovirus mediated gene transfer: (i) stable proviral transmission; (ii) high titer and/or efficient selection of transduced erythroid cells for sustained reconstitution of engrafted

individuals with infected bone marrow cells; (iii) high, position-independent and erythroid specific β -globin expression; (iv) safety.

Although the design of retroviral vectors transducing β -globin gene and β -LCR derivatives has been faced with important technical difficulties (Novak, U., Harris, E.A.S., Forrester, W., Groudine, M. and Gelinas, R. (1990) Proc. Natl. Acad. Sci., USA, 87, 3386-3390; Chang, J.C., Liu, D. and Kan, Y.W. (1992) Proc. Natl. Acad. Sci. USA, 89, 3107-3110; Plavec, I., Papayannopoulou, T., Maury, C. and Meyer, F. (1993) Blood, 81, 1384-1392), [β -globin/LCR] retroviral vectors capable of stable proviral transmission and high erythroid-specific β -globin mRNA expression have recently been obtained (Leboulch, P., Huang, G.M.S., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y.H. and London, I.M. (1994) EMBO J., 13 (1994)).

Figure 2 shows a schematic representation of the structure of the [β/δ -globin/HS2] retroviral vector, p#147. The β/δ SCI1 retroviral vector comprises from 5' to 3': (1) the Moloney Murine Sarcoma Virus (MoMSV) long terminal repeat (LTR) followed by the hybrid extended packaging signal of LXSN, (2) a mutated human β -globin gene in reverse genomic orientation driven by the human β -globin promoter, (3) the HS2 site from the human β -LCR in reverse genomic orientation, (4) the murine PGK-1 promoter in direct genomic orientation, (5) the Neo^R gene, (6) the Moloney Murine Leukemia Virus (MoMLV) polypurine track (PPT), and (7) a modified MoMLV LTR. The β -globin gene was inserted in reverse orientation with respect to the direction of transcription of the provirus to prevent splicing of the β -globin introns on the viral genomic RNA prior to reverse transcription. For safety and for the prevention of a possible antisense effect due to the reverse orientation of the transduced β -globin promoter, a self-inactivating LXSN vector was created by making a 176 bp [Pvu2-Xba1] deletion in the 3' LTR (Leboulch, P et. al., (1994)). The 5' border of the human β -globin promoter is the SnaB1 site 266 bp upstream of the β -globin mRNA cap site. The 30 bp downstream of the gene were retained for cleavage/polyadenylation. The HS2 element was a 374 bp [Hind3-Xba1] HS2 fragment from the human β -LCR (23, 24, 25, 26).

30

The human β -globin gene in [β globin/LCR/PGK]^{mut} retroviral vector also contains deletions and mutations that increase stability of proviral transmission and viral titers while being neutral for β -globin gene expression (Leboulch, P. et. al., (1994) The EMBO Journal 13:3065-3076). These modifications include: (1) a 372 bp deletion in β IVS2 between two Rsa1 sites located at + 580 and + 952 downstream from the human β -globin cap site, and (2) point mutations of complementary / reverse (C/R) polyadenylation signals (Poly A) and C/R splice sites (SS).

35

The [β/δ SCI1/HS2] retroviral vector p#147 was constructed as follows. A 430 bp [Nco1-BamH1] fragment of the human δ -globin gene, that contains the segment of the δ -globin gene described above, was used to replace the corresponding fragment of the human β -globin gene in the [β -globin/LCR/PGK]^{mut} retroviral vector (Figure 2). This substitution introduces 6 of the 10 codons specific for the δ -globin gene, including all the positions that encode "anti-sickling" residues identified by Nagel and colleagues. In exon III, two additional changes, [β 116His to d 116Arg] and [β 117His to d 117Asn], were introduced by recombinant polymerase chain reaction (PCR) with mutated primers used previously for deleting part of β IVS2 in the [β -globin/LCR/PGK]^{mut} retroviral vector (15) (Figure 2).

C/R SS and Poly A can lead to rearrangements of the transmitted proviral structures in [β -globin/LCR] retroviral vectors (Leboulch, P. et. al., (1994) The EMBO Journal 13:3065-3076)), the DNA sequence of the aforementioned [Nco1-BamH1] fragment of the human δ -globin gene for the presence of such deleterious features, using the same methodology previously employed (Leboulch, P. et. al., (1994) The EMBO Journal 13:3065-3076). No [AATAAA] signals were found. In contrast, several potentially dangerous C/R SS were identified. These include three 3'SS, [agCCTTCaCCTTAGG], [aCTTTgCCCCACAGG] and [agTCTTCTCCTCAGG], 111 bp, 372 bp and 398 bp downstream from the Nco1 site in C/R orientation, respectively. The two last 3'SS also possess well conserved branchpoint signals at an appropriate distance upstream. A well conserved 5'SS is also present, [CAGGTGAGC], 63 bp downstream from the Nco1 site in C/R orientation. Since proviral transmission of a non-mutated [β -globin/HS2/PGK] retroviral vector was stable when no additional LCR derivatives were incorporated in the vector (15), whether retroviral vector p#147 was stable was determined.

To study proviral transmission and to measure viral titers, MEL and NIH 3T3 cells were infected by exposure to viral supernatants from pooled ψ crip stable producer cells or from transiently transfected BOSC23 cells. Infected cells were subsequently selected with G418. Proviral transmission was analyzed by Southern blot using a Neo^R-specific probe after restriction digestion of genomic DNA with Sac1, which cuts only once in each LTR. Corresponding digested plasmids were used as size controls. Results from the Southern blot analysis indicate that proviral transmission was stable, without detected rearrangements. Viral titers, obtained from transiently transfected BOSC23 cells, were 2×10^4 cfu/ml for both the retroviral vector p#147 and [β -globin/HS2/PGK]^{mut}, indicating that these vectors had very similar transmission properties. In light of previous results with [β -globin/HS2/PGK]^{mut} producers (Leboulch, P. et. al., (1994) The EMBO Journal 13:3065-3076), the best independent p#147 ψ cre producers would be expected to reach titers above 10^5 cfu/ml. No helper virus was detected using a β -galactosidase mobilization assay in any of the viral producers.

β/δ -SCI1 mRNA expression levels in DMSO-induced MEL cells, which mimic adult erythroid differentiation were measured. MEL cells were infected with supernatants from amphotropic producers under experimental conditions that provided up to one integrated provirus per cell, and were subsequently selected with G418. Pools of at least one hundred infected and selected MEL cell clones were analyzed, either without induction or following exposure to DMSO for five days to induce terminal erythroid differentiation. Human and murine β -globin mRNA levels were measured by RNA protection assay using probes specific for DNA sequences in either murine β_{maj} - or human δ -globin mRNAs, as described in Example 1. The results demonstrate that human β/δ -SCI1 mRNA was properly initiated and spliced in infected MEL cells. The mRNA ratios were calculated on a per gene basis, with appropriate corrections. In infected (one provirus per cell), G418 selected, and DMSO-induced MEL cells, expression levels of β/δ -SCI1 mRNA using the p#147 virus reached 85% of murine β_{maj} -globin mRNA, corrected on a per-gene basis as described in the examples.

Gene Therapy

The high expression levels of vectors encoding anti-sickling β -globin proteins make them useful for gene therapies for preventing or reducing or eliminating the symptoms of Sickle Cell disease. Gene therapies can be performed by infecting erythroid cells with a vector encoding an anti-sickling β -globin protein as described above. In general, ex vivo gene therapy of Sickle Cell disease is performed on erythroid cells obtained from a subject's (e.g. human's or animal's) bone marrow, which had been removed (for example, by aspiration under sterile conditions). The bone marrow cells are then incubated with the vector. The treated bone marrow cells are then reinfused into the patient (e.g. via transplantation or grafting). The procedure can be repeated several times in order to increase the total number of marrow erythroid cells expressing the anti-sickling β globin protein. Alternatively, the erythroid cells can be obtained from a donor (i.e. a compatible source other than the recipient), modified and delivered to the recipient, again by transplanting or grafting.

Alternatively, an "effective amount" of vector encoding an anti-sickling β globin and a pharmaceutically acceptable carrier (e.g. saline) can be administered to a Sickle Cell disease subject directly. As used herein, an "effective amount" is an amount sufficient to reduce or eliminate the symptoms associated with Sickle Cell disease. The effective amount can be determined by one of skill in the art using no more than routine experimentation and may take into account such factors as the type and severity of symptoms being treated, the weight and/or age of the subject, the previous medical history of the subject and the selected route of administration. Exemplary modes of administration of an anti-sickling β globin gene

therapy vector includes subcutaneously, intravenously, intraperitoneally, intramuscularly, parenterally, submucosally, orally, transdermally or other appropriate manner. If necessitated by a particular mode of administration, an anti-sickling β globin gene therapy vector can be encapsulated within a material that protects it from enzymatic degradation.

5

The present invention is further illustrated by the following examples which should not be construed as limiting in any way. The contents of all cited references (including literature references, issued patents, published patent applications, and co-pending patent applications) cited throughout this application are hereby expressly incorporated by reference.

10

Example 1 Retroviral transfer of human δ -globin/ β -globin hybrid gene

DNA construction

15

The retroviral vector [β -globin/LCR/PGK]^{mut} has been described (Leboulch, P., Huang, G.M.S., Humphries, R.K, Oh, Y.H., Eaves, C.J., Tuan, D.Y.H. and London, I.M. (1994) EMBO J., 13, (1994)). It contains elements from the vector LXS_N (Miller, A.D. and Rosman, G.J. (1989) BioTechniques, 7, 980-990) provided by Dusty Miller (Fred Hutchinson Cancer Research Center, Seattle), and human b-LCR and β -globin gene sequences provided by Tom Maniatis (Harvard University, Cambridge) and Oliver Smithies (University of North Carolina, Chapel Hill). The δ -globin gene was provided by Oliver Smithies. The murine b_{maj}-globin gene was provided by Deborah Galson (Harvard Medical School, Boston). The murine phosphoglycerate kinase (PGK) -1 promoter/Neomycin phosphotransferase (Neo^R) cassette was provided by Rudolf Jaenisch (Whitehead Institute and MIT, Cambridge). All constructions were made using standard techniques (Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular cloning : a laboratory manual - 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA). Oligonucleotides were synthesized at the MIT Biopolymer Laboratory.

20

25

30

Production of recombinant retroviruses

35

The packaging cell lines ψ cre and ψ crip, provided by Richard Mulligan (Whitehead Institute and MIT, Cambridge), were grown as described (Danos, O. and Mulligan, R.C. (1988) Proc. Natl. Acad. Sci. USA, 85, 6460-6464). The packaging cell line BOS_C23, provided by David Pear and David Baltimore (Rockefeller University, New York), was grown as described (Paer, W.S., Nolan, G.P., Scott, M.L. and Baltimore, D. (1993) Proc. Natl. Acad. Sci., USA, 90, 8392-8396). Plasmid DNAs used for transfection were prepared by the Qiagen procedure (Qiagen, Inc). Since self-inactivating vectors were used, Plasmid

DNAs were directly transfected into packaging cells using a calcium phosphate procedure (5prime:3prime, Inc), after linearization of the Plasmids outside the proviral structure (NdeI site) for Ycre and Ycrip cells or without linearization for BOSC23 cells. Viral supernatants were harvested two days after transient transfection of BOSC23 cells, as described (Danos, O. and Mulligan, R.C. (1988) Proc. Natl. Acad. Sci. USA, 85, 6460-6464). Pools of Ycre and Ycrip producer cells were isolated and expanded following G418 selection (500 mg/ml active) (Gibco). Viruses were prepared by filtration of supernatants through 0.45 mm Millipore filters as described (Leboulch, P., Huang, G.M.S., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y.H. and London, I.M. (1994) EMBO J., 13, (1994); Danos, O. and Mulligan, R.C. (1988) Proc. Natl. Acad. Sci. USA, 85, 6460-6464). Detection of helper viruses was performed by a b-galactosidase mobilization assay as described (Danos, O. and Mulligan, R.C. (1988) Proc. Natl. Acad. Sci. USA, 85, 6460-6464).

Proviral transmission and virus titration

NIH 3T3 cells were infected with various dilutions of filtered viral supernatants in the presence of 8 mg/ml Polybrene (Sigma), as described ((Leboulch, P., Huang, G.M.S., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y.H. and London, I.M. (1994) EMBO J., 13, (1994); Danos, O. and Mulligan, R.C. (1988) Proc. Natl. Acad. Sci. USA, 85, 6460-6464). Cells were subsequently transferred to a medium containing 500 mg/ml active G418. Resistant colonies were counted, and titers were estimated by standard calculations previously described (Leboulch, P., Huang, G.M.S., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y.H. and London, I.M. (1994) EMBO J., 13, (1994); Danos, O. and Mulligan, R.C. (1988) Proc. Natl. Acad. Sci. USA, 85, 6460-6464). Proviral transmission was tested by Southern blot analysis of SacI-digested DNA from infected cells using a Neo^R-specific probe and appropriate plasmid controls.

Infection of MEL cells and RNA protection assays

Semi-adherent (APRT-) MEL cells were grown at 37°C with 5% CO₂ / 95% air in DMEM supplemented with 12% horse serum, 4.5 mg/ml glucose, 2 mM glutamine, 100 IU/ml penicillin and 100 mg/ml streptomycin. Infections of cells were performed with 3 ml of filtered supernatant from viral producers in the presence of 8 mg/ml Polybrene as described above. Infected cells were subsequently grown in medium containing 500 mg/ml active G418. Pools of resistant colonies were isolated and expanded. MEL cells were induced for 5 days at 37°C with 5% CO₂ / 95% air in DMEM supplemented with 15% fetal calf serum, 4.5 mg/ml glucose, 2 mM glutamine, 100 IU/ml penicillin, 100 mg/ml streptomycin and 2% dimethylsulfoxide (DMSO) (Sigma). Total RNA was extracted by the RNazol B method (Biotecx Laboratories, Inc). Quantitative RNA protection assays were

performed with uniformly labeled RNA probes *in vitro* transcribed using SP6 or T7 polymerase (Gibco) in the presence of [α - 32 P] UTP (Amersham). RNA protection assays were performed as described (Leboulch, P., Huang, G.M.S., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y.H. and London, I.M. (1994) *EMBO J.*, 13, (1994); Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) *Molecular cloning : a laboratory manual - 2nd ed.* Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, USA), with the following conditions: 10 mg of total RNA, $> 5 \times 10^5$ cpm of each probe in separate reactions, hybridization at 52°C for 16 hours in [40 mM PIPES, pH6.4, 400mM NaCl, 1mM EDTA, 80% formamide], followed by digestion with 20 mg/ml RNase A (Sigma) and 2 mg/ml RNase T1 (Sigma) for 30 min at room temperature. RNA protection samples containing murine β -globin and human δ -globin probes were combined at 1:2 ratio prior to loading onto a 6% polyacrylamide gel. A human δ -globin-specific probe was constructed by sub-cloning a T7 promoter in reverse genomic orientation at the BamH1 site of d exon II, and linearizing the template prior to *in vitro* transcription at the Nco1 site that overlaps the initiator "ATG" in d exon I. The specific protected fragment is 210 bp long and corresponds to most of d exon II up to the exonic BamH1 site. A murine-specific probe, previously described (Leboulch, P., Huang, G.M.S., Humphries, R.K., Oh, Y.H., Eaves, C.J., Tuan, D.Y.H. and London, I.M. (1994) *EMBO J.*, 13, (1994)), was used as an internal control for murine endogenous mRNA expression. This probe protects a 145 bp fragment corresponding to exon I of the murine β_{maj} -globin mRNA. Because of extensive homology between β_{maj} - and β_{min} - globin mRNAs and the conditions of our RNA protection assay, the murine specific probe also protects a 115 bp fragment of the murine β_{min} -globin mRNA, upon cleavage at a cluster of mismatches. Radioactive bands corresponding to the specific protected fragments were scanned using a Phosphor Imager (Molecular Dynamics). The mRNA ratios were calculated on a per gene basis in MEL cells, which are pseudo-diploid for the endogeneous murine globin genes (correction factor: 2). The mRNA ratio was also corrected for the number of uridine residues in each probe (44 for human d and 33 for murine β_{maj} ; correction factor: 1.3). Global calculations were made as follows:

$$\frac{\text{Human } \delta}{\text{Murine } \beta \text{ maj}} = \frac{[\text{Human } \delta\text{-globin band}] \times 2 \times 100}{2 \times [\text{Murine } \beta \text{ maj-globin band}] \times 1.3}$$

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents of the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

5

(i) APPLICANT: Massachusetts Institute of Technology

(ii) TITLE OF INVENTION: Compositions and Methods for
Treating Sickle Cell Disease

10

(iii) NUMBER OF SEQUENCES: 2

(iv) CORRESPONDENCE ADDRESS:

15

(A) ADDRESSEE: LAHIVE & COCKFIELD

(B) STREET: 60 State Street, suite 510

(C) CITY: Boston

(D) STATE: Massachusetts

(E) COUNTRY: USA

(F) ZIP: 02109-1875

20

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

25

(D) SOFTWARE: ASCII text

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:

(B) FILING DATE: Herewith

30

(C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:

(A) APPLICATION NUMBER: US 08/308,795

(B) FILING DATE: 19-SEPTEMBER-1994

35

(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Giulio A. DeConti, Jr.

(B) REGISTRATION NUMBER: 31,503

40

(C) REFERENCE/DOCKET NUMBER: MTE-185PC

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617)227-7400

(B) TELEFAX: (617)227-5941

45

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

50

(A) LENGTH: 146 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

55

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5 Val His Leu Thr Pro Glu Glu Lys Ser Ala Val Thr Ala Leu Trp Gly
1 5 10 15

Lys Val Asn Val Asp Glu Val Gly Gly Glu Ala Leu Gly Arg Leu Leu
20 25 30

10 Val Val Tyr Pro Trp Thr Gln Arg Phe Phe Glu Ser Phe Gly Asp Leu
35 40 45

Ser Thr Pro Asp Ala Val Met Gly Asn Pro Lys Val Lys Ala His Gly
50 55 60

15 Lys Lys Val Leu Gly Ala Phe Ser Asp Gly Leu Ala His Leu Asp Asn
65 70 75 80

20 Leu Lys Gly Thr Phe Ala Thr Leu Ser Glu Leu His Cys Asp Lys Leu
85 90 95

His Val Asp Pro Glu Asn Phe Arg Leu Leu Gly Asn Val Leu Val Cys
100 105 110

25 Val Leu Ala His His Phe Gly Lys Glu Phe Thr Pro Pro Val Gln Ala
115 120 125

Ala Tyr Gln Lys Val Val Ala Gly Val Ala Asn Ala Leu Ala His Lys
130 135 140

30 Tyr His
145

(2) INFORMATION FOR SEQ ID NO:2:

- 35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 146 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear
- 40 (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

50 Val His Leu Thr Pro Glu Glu Lys Thr Ala Val Asn Ala Leu Trp Gly
1 5 10 15

Lys Val Asn Val Asp Ala Val Gly Gly Glu Ala Leu Gly Arg Leu Leu
20 25 30

55 Val Val Tyr Pro Trp Thr Gln Arg Phe Phe Glu Ser Phe Gly Asp Leu
35 40 45

Ser Ser Pro Asp Ala Val Met Gly Asn Pro Lys Val Lys Ala His Gly
50 55 60

Claims

- 5 1. An anti-sickling β -globin protein comprising a conformationally correct β globin in which at least one amino acid residue has been substituted with a corresponding, anti-sickling residue.
2. An anti-sickling β -globin protein of claim 1, wherein the β -globin protein is human.
- 10 3. An anti-sickling β -globin protein of claim 2, wherein the anti-sickling residue is selected from the group consisting of: 9 Thr, 12 Asn, 22 Ala, 50 Ser, 86 Ser, 87 Gln, 116 Arg, 117 Asn, 125 Gln and 126 Met.
- 15 4. An anti-sickling β -globin protein having the amino acid sequence shown in SEQ. I.D. NO. 2.
5. Genetic material encoding the anti-sickling β -globin protein of claim 1.
6. The genetic material of claim 5, which is DNA.
- 20 7. The genetic material of claim 5, which is RNA.
8. A DNA construct comprising the genetic material of claim 6 and genetic material encoding a promoter recognized by a DNA polymerase.
- 25 9. The DNA construct of claim 8, wherein the DNA polymerase is erythroid specific.
10. The DNA construct of claim 9, wherein the promoter is selected from the group consisting of the β globin promoter and the HPFH promoter.
- 30 11. The DNA construct of claim 8 additionally comprising an enhancer.
12. The DNA construct of claim 11, wherein the enhancer is the the DNase I hypersensitive site 2 of the human β Locus Control Region and/ or the second intron of the β globin gene.
- 35 13. The DNA construct of claim 11, additionally comprising genetic material encoding a selectable marker under the control of the same or an additional promoter.

14. An RNA construct comprising the genetic material of claim 7 and genetic material encoding a promoter recognized by an erythroid RNA polymerase.

5 15. The RNA construct of claim 14, wherein the RNA polymerase is erythroid specific.

16. The RNA construct of claim 15, additionally comprising an enhancer.

10 17. The RNA construct of claim 16, additionally comprising genetic material encoding a selectable marker under the control of the same or an additional promoter.

18. A vector comprising the DNA construct of claim 13; and elements for infecting and stably maintaining the DNA in erythroid cells

15

19. The vector of claim 18 wherein the elements are selected from the group consisting of: retrovirus, adenovirus, adeno-associated virus, naked plasmid, lipid delivery of plasmid (including via liposomes), receptor mediated delivery of plasmid, alone, or in conjunction with transferring DNA-polylysine complexes linked to adenovirus capsids. A particularly preferred vector comprises retroviral elements.

20

20. The vector of claim 19, wherein the elements for infecting and stably maintaining the DNA in erythroid cells are retrovirus elements.

25

21. A method for treating sickle cell disease comprising the steps of:

a) obtaining erythroid cells;

30

b) contacting the erythroid cells with a vector encoding an anti-sickling β -globin protein, thereby producing erythroid cells expressing anti-sickling β -globin protein;

c) selecting the erythroid cells expressing anti-sickling β -globin protein; and

35

d) introducing the erythroid cells expressing anti-sickling β -globin protein into the subject.

22. A method for treating sickle cell disease in a subject comprising administering to the subject a vector encoding an anti-sickling β -globin protein in a pharmaceutically acceptable carrier.


5 23. A method of claim 22, wherein the vector is selected from the group consisting of: retrovirus, adenovirus, adeno-associated virus, naked plasmid, lipid delivery of plasmid (including via liposomes), receptor mediated delivery of plasmid, alone, or in conjunction with transferring DNA-polylysine complexes linked to adenovirus capsids. A particularly preferred vector comprises retroviral elements.

10 24. Erythroid cells expressing an anti-sickling β -globin protein.

 25. The erythroid cells of claim 3 selected from the group consisting of: stem cells, burst forming unit cells, colony forming unit cells, nucleated red blood cells and mature
15 red blood cells.

 26. The erythroid cells of claim 24 which are stem cells.

FIGURE 2



INTERNATIONAL SEARCH REPORT

Internr | Application No
PCT/US 95/11873

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/12 C07K14/805 A61K38/42 A61K48/00 C12N15/86
 C12N5/10 //C12N15/85,C12N15/87

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07K C12N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|--|-----------------------|
| P,X | WO,A,95 00657 (UAB RESEARCH FOUNDATION) 5 January 1995 see the whole document --- | 1-3 |
| P,X | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 92 (7). 1995. 3014-3018. ISSN: 0027-8424, 28 March 1995 TAKEKOSHI K J ET AL 'Retroviral transfer of a human beta - globin -delta- globin hybrid gene linked to beta locus control region hypersensitive site 2 aimed at the gene therapy of sickle cell disease.' see the whole document --- | 1-3 |
| P,X | WO,A,94 29470 (MASSACHUSETTS INST TECHNOLOGY) 22 December 1994 see the whole document --- | 24-26 |
| -/-- | | |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

12 December 1995

Date of mailing of the international search report

11. 01. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Hix, R

INTERNATIONAL SEARCH REPORT

 Intern al Application No
 PCT/US 95/11873

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|---|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| P,X | PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 91 (21). 1994. 9852-9856. ISSN: 0027-8424, October 1994 MCCUNE S L ET AL 'Recombinant human hemoglobins designed for gene therapy of sickle cell disease.' see the whole document --- | 1-3 |
| X | J BIOL CHEM 251 (20). 1976 6426-6430. CODEN: JBCHA3 ISSN: 0021-9258, EASTLAKE A ET AL 'THE AMINO TERMINAL REGION OF THE BETA CHAIN OF SICKLE HEMO GLOBIN PART 1 SYNTHESIS AND PURIFICATION OF OLIGO PEPTIDES.' see the whole document --- | 1,2 |
| X | J BIOL CHEM 251 (5). 1976 1290-1295. CODEN: JBCHA3 ISSN: 0021-9258, CURD J G ET AL 'ANTIBODIES TO AN AMINO TERMINAL FRAGMENT OF BETA -S GLOBIN PART 2 SPECIFICITY AND ISOLATION OF ANTIBODIES FOR THE SICKLE MUTATION.' see the whole document --- | 1,2 |
| Y | PROC. NATL. ACAD. SCI. USA, vol. 86, September 1989 pages 7033-7037, T.ENVER ET AL. 'The human beta-globin locus activation region alters the developmental fate of a human fetal globin gene in transgenic mice.' see the whole document --- | 24-26 |
| Y | WO,A,89 02469 (MASSACHUSETTS INST TECHNOLOGY) 23 March 1989 see the whole document --- | 24-26 |
| A | BLOOD 58 (2). 1981. 300-308. CODEN: BLOOAW ISSN: 0006-4971, ROTH E F JR ET AL 'CHEMICAL MODIFICATION OF HUMAN HEMO GLOBIN BY ANTI SICKLING CONCENTRATIONS OF NITROGEN MUSTARD.' see the whole document --- | 1-26 |
| A | WO,A,91 19505 (RES CORP TECHNOLOGIES INC) 26 December 1991 see the whole document --- | 1-26 |
| | -/-- | |

INTERNATIONAL SEARCH REPORT

Intern: I Application No
PCT/US 95/11873

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | <p>THE JOURNAL OF IMMUNOLOGY, vol. 121, no. 6, December 1978 pages 2458-2462, S. OTIENO ET AL. 'Specific antibodies to hemoglobin A1 {anti-Glu} and hemoglobin S {anti-Val} in the guinea pig: Immunologic and structural correlations.' see the whole document -----</p> | 1-26 |

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/ 11873

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 21,22,23
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 21,22,23 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No
PCT/US 95/11873

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| WO-A-9500657 | 05-01-95 | NONE | |
| WO-A-9429470 | 22-12-94 | NONE | |
| WO-A-8902469 | 23-03-89 | AT-T- 123059 | 15-06-95 |
| | | DE-D- 3853886 | 29-06-95 |
| | | DE-T- 3853886 | 05-10-95 |
| | | EP-A- 0377676 | 18-07-90 |
| | | JP-T- 3500245 | 24-01-91 |
| | | US-A- 5126260 | 30-06-92 |
| WO-A-9119505 | 26-12-91 | US-A- 5239061 | 24-08-93 |